

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 09th November, 2023

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited (DCS/Compliance) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), National Stock Exchange of India Limited, Exchange Plaza, C-1, Block G, BandraKurla Complex, Mumbai – 400051
---	--

Sub: Submission of Un-Audited Financial Results of the Company for the quarter as well as half year ended on 30th September, 2023 along with Segment results, Statement of Assets and Liabilities and Cash Flow Statement with Limited Review Report in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

This is in continuation of our letter dated 1st November, 2023 regarding information of Board Meeting for consideration and approval of Un-audited Financial Results for the quarter as well as and half year ended on 30th September, 2023.

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are here enclosing the Un-Audited Financial Results for the quarter as well as half year ended on 30th September, 2023 duly approved by the Board of Directors at its meeting held today i.e. Thursday, 09th November, 2023 together with Segment results, Statement of assets and liabilities, Cash Flow Statement and Limited Review Report thereon. ***Copy of Un-audited Financial Results along with Limited Review Report is enclosed with this letter (searchable PDF mode).***

Further above said results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid financial results shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com & www.nseindia.com and extracts of the aforesaid results shall also be published in Hindi (Vernacular) and widely circulated English Newspaper.

You are requested to take on record the above said financial results for your reference and record.

Thanking you.

Yours Faithfully,

FOR, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

SHWETA VERMA
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A70184

Enclosure: Un-Audited Financial Results along with limited review report for the quarter as well as half year ended on 30th September, 2023.

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN: L24233MP1985PLC002709


Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718,

Website: www.biofilgroup.net

(Amount in Lakhs except EPS)

Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2023

Particulars	Quarter Ended			Half Year Ended		Previous Year Ended
	3 Month Ended 30/09/2023	3 Month Ended 30/06/2023	Corresponding 3 months ended in the previous year (30/09/2022)	Year to date figures for current period ended (30/09/2023)	Year to date figures for the previous year ended (30/09/2022)	Previous year ended on March 31 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from Operation	1736.76	243.35	261.96	1980.11	1492.52	3003.52
II Other Income	3.15	2.47	2.35	5.62	4.03	9.70
III Total Income (I + II)	1739.91	245.82	264.30	1985.73	1496.55	3013.22
IV Expenses						
(a) Cost of materials consumed	1292.24	135.51	77.55	1427.75	143.20	391.835
(b) Purchases of stock-in-trade	708.81	80.50	138.27	789.31	1186.30	2370.63
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(330.98)	(54.97)	(2.26)	(385.95)	39.11	(20.13)
(d) Employee benefits expense	16.28	16.06	14.49	32.34	29.58	62.38
(e) Finance Cost	0.97	1.09	1.06	2.06	2.19	4.25
(f) Depreciation and Amortisation Expense	10.73	10.73	10.69	21.47	21.37	42.91
(g) Other expenses						
1. Manufacturing Expenses	15.95	11.92	10.90	27.87	21.69	47.34
2. Administrative Expenses	9.43	11.64	5.73	21.07	16.04	29.50
3. Selling and Distribution Expenses	1.19	0.92	1.79	2.11	3.42	5.21
Total expenses (IV)	1724.61	213.40	258.22	1938.0	1462.91	2933.93
V Profit/ (Loss) before exceptional items and tax (III-IV)	15.29	32.42	6.08	47.71	33.64	79.29
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII Profit/ (Loss) before tax (V - VI)	15.29	32.42	6.08	47.71	33.64	79.29
VIII Tax expense:						
(1) Current tax	3.00	8.00	1.53	11.00	8.47	23.00
(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	0.26
Total Tax expenses	3.00	8.00	1.53	11.00	8.47	23.26
IX Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
X Profit/(Loss) for the period from continuing operation (VII-VIII)	12.29	24.42	4.55	36.70	25.17	56.03
XI Profit/(Loss) from dis-continued operation before tax	0.00	0.00	0.00	0.00	0.00	0.00
XII Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XIII Profit/(Loss) from dis-continued operation after tax (XI-XII)	0.00	0.00	0.00	0.00	0.00	0.00
XIV Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
XV Profit/ (Loss) for the period (X+XIII)	12.29	24.42	4.55	36.70	25.17	56.03
XVI Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	
A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(12.91)
(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	3.25
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00




	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	12.29	24.42	4.55	36.70	25.17	46.37
XVIII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XIX	Reserves (Excluding Revaluation Reserve)						(273.44)
XX	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.08	0.15	0.03	0.23	0.15	0.28
	(2) Diluted (Rs)	0.08	0.15	0.03	0.23	0.15	0.28
XXI	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XXII	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.08	0.15	0.03	0.23	0.15	0.28
	(2) Diluted (Rs)	0.08	0.15	0.03	0.23	0.15	0.28

- The above unaudited results for the Quarter and half year ended Sept. 30, 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on November 09, 2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
- Pharma Division
 - Chemicals Division.
- The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

Date : 09-11-2023

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



Ramesh Shah
RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718,


Website: www.biofilgroup.net

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2023

Particulars	(Amount in Lakhs)	
	As at 30/09/2023 Unaudited	As at 31/03/2023 Audited
A ASSETS		
1 Non-current assets:		
(a) Property, Plant & Equipment	878.61	900.07
(b) Capital work in Progress		
(c) Investment Property		
(d) Goodwill		
(e) Other Intangible assets		
(f) Intangible Assets under development		
(g) Biological Assets other than bearer plants		
(h) Financial Assets:		
i. Investments		
ii. Trade receivables		
iii. Loans		
iv. Others (to be specified)		
(i) Deferred tax assets (net)		
(j) Other Non- Current Assets		
Sub-total - Non-current assets	878.61	900.07
2 Current assets		
(a) Inventories	507.30	121.34
(b) Financial Assets:		
(i) Investment		
(ii) Trade receivables	2739.81	2,050.27
(iii) Cash and cash equivalents	3.45	2.60
(iv) Bank balances other than (iii) above	2.30	1.17
(v) Loans		
(vi) Others (to be specified)		
(c) Current Tax Assest (Net)		
(d) Other Currents Assets	90.16	65.12
Sub-total - Current assets	3,343.01	2,240.50
TOTAL - ASSETS	4,221.62	3,140.57
B EQUITY AND LIABILITIES		
1 Equity		
(i) Equity Share Capital	1627.38	1,627.38
(ii) Other Equity	139.66	102.77
Sub-total- Equity	1767.04	1,730.15
2 Liabilities		
Non-current Liabilities :		
a. Financial Liabilities		
(i) Borrowings		
(ia) Lease Liabilities		
(ii) Trade Payable		
(a) total outstanding dues of micro enterprises and small enterprises; and		
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.		
(iii) other Financial Liabilities (other than those specified in item (b), to be specified)		
b. Provisions		
c. Deferred tax liabilities (net)	37.87	37.87
d. Other Non-current Liabilities		
Sub-total - Non-current liabilities	1,804.91	1,768.02
3 Current liabilities		
a. Financial Liabilities		
(i) Borrowings	56.40	52.23
(ia) Lease Liabilities		
(ii) Trade Payables :-		
(a) total outstanding dues of micro enterprises and small enterprises; and		
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	2328.82	1,264.99
(iii) other Financial Liabilities [other than those specified in item (C)]	0.00	
b. Other Current Liabilities	11.00	32.33
c. Provisions	20.49	23.00
d. Current Tax Liabilities (Net)		
Sub-total - Current liabilities	2,416.71	1,372.55
TOTAL - EQUITY AND LIABILITIES	4,221.62	3,140.57

Date : 09-11-2023

Place : Indore



FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.


Ramesh Shah
RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)

Reporting of Segment wise Revenue, Results and Capital Employed for quarter and half year ended 30th September 2023

		(Amount in Lakhs)					
S.No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2023	Preceeding 3 Month Ended 30/06/2023	Corresponding 3 months ended in the previous year (30/09/2022)	Year to date figures for current period ended (30/09/2023)	Year to date figures for the previous year ended (30/09/2022)	Previous Year ended March 31 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Unit	1,010.69	81.90	141.94	1,092.59	1,203.12	2,419.61
	Chemicals Division	726.07	161.45	120.02	887.52	289.39	583.91
	Gross Turnover	1,736.76	243.35	261.96	1,980.11	1,492.52	3,003.52
2	Segment Results						
	Pharma Unit	(0.88)	(17.05)	(13.87)	(17.93)	(16.65)	(14.58)
	Chemicals Division	16.97	50.49	21.00	67.46	52.43	97.91
	Total Segment Profit Before Tax	16.09	33.44	7.13	49.53	35.79	83.33
	Interest Income	0.04	0.03	0.01	0.06	0.03	0.16
	Interest Expenses	0.83	1.05	1.05	1.88	2.18	4.19
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	15.29	32.42	6.08	47.71	33.64	79.30
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	1,928.06	1,636.46	2,012.21	1,928.06	2,012.21	1,705.77
	Chemicals Division	2,237.35	1,550.22	1,299.99	2,237.35	1,299.99	1,434.80
	Total (A)	4,165.42	3,186.68	3,312.20	4,165.42	3,312.20	3,140.57
	Segment Liabilities (B)						
	Pharma Division	1,567.53	1,185.84	1,454.74	1,567.53	1,454.74	1,142.60
	Chemicals Division	830.85	208.40	148.51	830.85	148.51	267.83
	Total (B)	2,398.38	1,394.24	1,603.26	2,398.38	1,603.26	1,410.42
	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	360.53	450.62	557.47	360.53	557.47	563.17
	Chemicals Division	1,406.50	1,341.83	1,151.47	1,406.50	1,151.47	1,166.98
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,767.04	1,792.44	1,708.94	1,767.04	1,708.94	1,730.15

Date : 09-11-2023

Place : Indore



FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ramesh Shah

RAMESH SHAH

CHAIRMAN & MANAGING DIRECTOR

(DIN: 00028819)

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net


Statement of cash flows for the year half year ended 30th Sept 2023

(Amount in Lakhs)

Particulars	HALF YEAR ENDED ON 30.09.23	HALF YEAR ENDED ON 30.09.22
	Unaudited	Unaudited
Cash flow from operating activities		
Profit before tax	47.71	33.64
Adjustments to reconcile profit before tax to net cash used in operating activities		
Depreciation of property, plant and equipment	21.47	21.37
Finance cost	2.06	2.19
Impact Considered in OCI		
Net (gain)/ loss on derivative contracts on account of Ind AS adjustments		
Provision for doubtful advances/debts	71.23	57.20
Working capital adjustments		
Increase/ (Decrease) in Inventory	(385.95)	39.11
(Increase)/ Decrease in Trade Receivable	(689.54)	(1513.74)
(Increase)/ Decrease in other current assets	(25.04)	16.97
Increase/ (Decrease) in trade payables	1063.83	1434.02
Increase/ (Decrease) in other financial liabilities	0.00	0.00
Increase/ (Decrease) in other liabilities	(7.27)	(7.32)
Cash generated from operations	27.27	26.23
Payment of Income Tax/Provision	(27.40)	(25.25)
Net cash flows from operating activities	(0.13)	0.99
Cash flow from investing activities		
Payment for purchase and construction of property, plant and equipment	0.00	(1.06)
Proceeds from sale of property, plant and equipment	0.00	0.00
(Increase)/ Decrease in other bank balances		
Interest received		
Net cash flows from investing activities	0.00	(1.06)
Cash flow from financing activities		
Increase/ (decrease) in Borrowings	4.16	3.88
Deemed Investment by Holding Company		
Finance cost	(2.06)	(2.19)
Net cash flows from financing activities	2.11	1.69
Net increase / (decrease) in cash and cash equivalents	1.98	1.63
Cash and cash equivalents at the beginning of the year	3.76	14.50
Cash and cash equivalents at the end of the year	5.74	16.13
Increase / (Decrease) in cash and cash equivalents	1.98	1.63

Date: 09/11/2023

Place: INDORE



BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ramesh Shah
RAMESH SHAH
 CHAIRMAN & MANAGING DIRECTOR
 (DIN 00028819)



Limited Review Report on the Quarterly Unaudited and Year to date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 30th September, 2023 and year to date from 1st April, 2023 to 30th September, 2023. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India.





has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Date: 09th November, 2023
Place: Indore

For Maheshwari & Gupta
Chartered Accountants
FRN: 006179C



CA Sunil Maheshwari
Partner

M No 403346

UDIN: 23403346 BG UKRS 4073